BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33547212)

  • 21. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
    PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
    Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
    Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
    Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
    Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of
    Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
    Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y; Yoshida M; Sato M; Sato K; Kikuchi S; Sugishita H; Kuwabara J; Matsuno Y; Kojima Y; Morimoto M; Horiuchi A; Watanabe Y
    Int J Oncol; 2011 Jan; 38(1):33-9. PubMed ID: 21109923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of
    Vinod N; Kim JH; Choi S; Lim I
    Sci Rep; 2021 Jun; 11(1):12871. PubMed ID: 34145369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.
    Kang CS; Song HA; Milenic DE; Baidoo KE; Brechbiel MW; Chong HS
    Nucl Med Biol; 2013 Jul; 40(5):600-5. PubMed ID: 23541026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
    Boudousq V; Bobyk L; Busson M; Garambois V; Jarlier M; Charalambatou P; Pèlegrin A; Paillas S; Chouin N; Quenet F; Maquaire P; Torgue J; Navarro-Teulon I; Pouget JP
    PLoS One; 2013; 8(7):e69613. PubMed ID: 23922757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
    Pereira PMR; Mandleywala K; Ragupathi A; Carter LM; Goos JACM; Janjigian YY; Lewis JS
    J Nucl Med; 2019 Nov; 60(11):1569-1578. PubMed ID: 31171598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
    Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validating α-particle emission from 211At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors.
    Kodaira S; Li HK; Konishi T; Kitamura H; Kurano M; Hasegawa S
    PLoS One; 2017; 12(6):e0178472. PubMed ID: 28658304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.